Incyte Corporation INCY
123.36
(1.46)
(1.17%)
as of 29 Sep
- Market cap
- $26.1B
- P/E
- 15.4×
Follow INCY
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Incyte Corporation (INCY) EBITDA
Incyte Corporation's EBITDA for fiscal 2025 was $1.6B, up 967.7% from $150.6M in fiscal 2024. Over the twelve months to 30 June 2026 it was $1.9B. Over the past ten years it has ranged from −$211.9M (fiscal 2020) to $1.6B (fiscal 2025) — the current reading is the highest in ten years. Incyte Corporation ranks 3rd of 602 Biotechnology companies by EBITDA.
EBITDA, annual
Annual
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $1.6B | 967.73% |
| FY2024 | $150.6M | (78.58%) |
| FY2023 | $703.2M | 8.63% |
| FY2022 | $647.3M | 0.57% |
| FY2021 | $643.6M | — |
| FY2020 | −$211.9M | — |
| FY2019 | $456.5M | 147.86% |
| FY2018 | $184.2M | — |
| FY2017 | −$191.2M | — |
| FY2016 | $203.4M | 112.93% |
Quarterly
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $724.4M | 122.94% |
| Mar 2026 | $324.9M | (9.70%) |
| Dec 2025 | $359.8M | (23.04%) |
| Sep 2025 | $467.5M | (15.49%) |
| 42 more quarters | Free account |
Against its own ten years
Low −$211.9M
High $1.6B
Ten-year median
$203.4M
Current reading's percentile
100
EBITDA against peers
| Company | EBITDA |
|---|---|
| INCY Incyte Corporation | $1.9B |
| JAZZ Jazz Pharmaceuticals PLC compare | $1.6B |
| RPRX Royalty Pharma PLC compare | $1.5B |
| GMAB Genmab A/S Sponsored ADR compare | $1.2B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $1.1B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $1.1B |
| ROIV Roivant Sciences Ltd. compare | −$593.3M |
| INSM Insmed, Inc. compare | −$812.5M |
| BNTX BioNTech SE Sponsored ADR compare | −$1.6B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on INCY
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement